Elicio Therapeutics Stock In The News

ELTX Stock   4.88  0.20  3.94%   
Our overall analysis of Elicio Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Elicio Therapeutics. The specific impact of Elicio Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Elicio Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Elicio Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Elicio Therapeutics Backtesting and Elicio Therapeutics Hype Analysis.
For more information on how to buy Elicio Stock please use our How to Invest in Elicio Therapeutics guide.

Elicio Therapeutics Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
https://www.globenewswire.com/news-release/2023/11/09/2777902/0/en/Elicio-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Updates.html
 Neutral
Macroaxis News: globenewswire.com
Elicio Therapeutics Presents Updated Pre...
https://www.globenewswire.com/news-release/2023/11/03/2773455/0/en/Elicio-Therapeutics-Presents-Updated-Preliminary-Immunogenicity-Data-from-the-Ongoing-Phase-1-Study-of-ELI-002-and-New-Preclinical-Data-on-ELI-007-and-ELI-008-at-the-Society-for-Im.html
 Neutral
Macroaxis News: globenewswire.com
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
https://www.globenewswire.com/news-release/2023/10/11/2758314/0/en/Elicio-Therapeutics-Announces-Upcoming-Presentations-at-the-Society-for-Immunotherapy-of-Cancer-s-SITC-2023-Annual-Meeting.html
 Neutral
Macroaxis News: globenewswire.com
Elicio Therapeutics Presents Updated Pre...
https://www.globenewswire.com/news-release/2023/09/27/2750791/0/en/Elicio-Therapeutics-Presents-Updated-Preliminary-Data-Including-Promising-Relapse-Free-Survival-Data-from-the-Phase-1-Study-of-ELI-002-at-AACR-Special-Conference-Pancreatic-Cancer.html
 Neutral
Macroaxis News: globenewswire.com
Elicio Therapeutics Receives $2.6 Millio...
https://www.globenewswire.com/news-release/2023/09/07/2739266/0/en/Elicio-Therapeutics-Receives-2-6-Million-Grant-from-the-Gastro-Intestinal-GI-Research-Foundation-to-Fund-Research-for-Two-Therapeutic-Cancer-Vaccines.html
 Bullish
Macroaxis News: globenewswire.com
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
https://www.globenewswire.com/news-release/2023/09/06/2738299/0/en/Elicio-Therapeutics-to-Present-at-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html
 Neutral
Macroaxis News: globenewswire.com
Elicio Therapeutics to Present Phase 1 D...
https://www.globenewswire.com/news-release/2023/09/05/2737295/0/en/Elicio-Therapeutics-to-Present-Phase-1-Data-on-Cancer-Vaccine-Candidate-ELI-002-in-Patients-with-High-Relapse-Risk-Pancreatic-and-Colorectal-Cancers-at-the-AACR-Special-Conference-.html
 Neutral
Macroaxis News: globenewswire.com
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
https://www.globenewswire.com/news-release/2023/08/28/2732545/0/en/Elicio-Therapeutics-Announces-Appointment-of-Megan-Filoon-as-General-Counsel-and-Dr-Thian-Kheoh-as-Senior-Vice-President-of-Biometrics.html
 Neutral
Macroaxis News: globenewswire.com
Elicio Therapeutics Reports Inducement Grants
https://www.globenewswire.com/news-release/2023/08/22/2730012/0/en/Elicio-Therapeutics-Reports-Inducement-Grants.html
 Neutral
Macroaxis News: globenewswire.com
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
https://www.globenewswire.com/news-release/2023/08/11/2723550/0/en/Elicio-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Updates.html
 Neutral

Elicio Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Elicio and other traded companies coverage with news coverage. We help investors stay connected with Elicio headlines for the 22nd of December to make an informed investment decision based on correlating the impacts of news items on Elicio Stock performance. Please note that trading solely based on the Elicio Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Elicio Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Elicio Therapeutics investors visualize upcoming and past events in order to time the market based on Elicio Therapeutics noise-free hype analysis.
Elicio Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Elicio earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Elicio Therapeutics that are available to investors today. That information is available publicly through Elicio media outlets and privately through word of mouth or via Elicio internal channels. However, regardless of the origin, that massive amount of Elicio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Elicio Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Elicio Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Elicio Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Elicio Therapeutics alpha.

Elicio Largest EPS Surprises

Earnings surprises can significantly impact Elicio Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-13
2024-06-30-0.96-0.640.3233 
2022-05-17
2022-03-31-4.35-4.8-0.4510 
2023-11-09
2023-09-30-0.8-1.27-0.4758 
2022-11-14
2022-09-30-3.6-3.00.616 
2024-11-07
2024-09-30-0.73-1.39-0.6690 
2024-03-29
2023-12-31-0.78-1.75-0.97124 
View All Earnings Estimates

Elicio Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Elicio Therapeutics Stock. The global stock market is bearish. About 65% of major world exchanges and indexes are down. See today's market update for more information.
Macroaxis News
16th of December 2024
Disposition of 381 shares by Peter DeMuth of Elicio Therapeutics at 4.41 subject to Rule 1...
at MacroaxisInsider 
Google News at Macroaxis
11th of December 2024
Investment Analysis and Advice - Stock Traders Daily
at news.google.com 
Google News at Macroaxis
22nd of November 2024
SEC Form 424B3 filed by Elicio Therapeutics Inc. - Quantisnow
at news.google.com 
Yahoo News
7th of November 2024
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P St...
at finance.yahoo.com 
Google News at Macroaxis
16th of October 2024
Elicio Therapeutics Reports Inducement Grants - StockTitan
at news.google.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Elicio Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Elicio Therapeutics' short interest history, or implied volatility extrapolated from Elicio Therapeutics options trading.

Additional Tools for Elicio Stock Analysis

When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.